Comera Life Sciences Reports Financial Results for First Quarter 2023 and Recent Business Highlights
- Significant progress in Comera's ongoing research collaboration with Regeneron, a leading U.S. biotechnology company - - Further development of Comera's pipeline candidate CLS-001 (SQ vedolizumab),